CTOs on the Move

NovaTec Consultants

www.novatec.ca

 
NovaTec Consultants, Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.novatec.ca
  • 2415 Columbia St
    Vancouver, BC CAN V5Y 3E7
  • Phone: 604.873.9262

Executives

Name Title Contact Details

Similar Companies

Premiera Care Communities

Premiera Care Communities is a Oakdale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Corium International

Corium International is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neoleukin

Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.

Bio-Solutions Corporation

Bio-Solutions Corp, Owns and Markets Type2 Defense(TM), a glucose control dietary supplement powder formulated to support healthy glucose levels in addition to maintaining healthy blood pressure.   The company believes that there is a growing Diabetic target market place that lacks adequate healthy tools to maintain healthy blood glucose levels. Type2 Defense is a powder blend of natural ingredients that has been developed to maintain healthy blood glucose levels.

Evolve Biosystems

Evolve BioSystems is a spin-out from the Foods For Health Institute (FFHI) at the University of California, Davis. The company builds on more than a decade of research into the infant gut microbiome and its unique interaction with breast milk components, established by the founding scientists including Bruce German, David Mills, Carlito Lebrilla, Daniela Barile and Samara Freeman. Their fundamental research and translational clinical trials have been enabled by more than $15 million in federal and private grants since 2004. Under the leadership of CEO Dr. David Kyle, Evolve completed a $1 million seed funding round in mid-2014, a $9 million Series A round in August 2015 and most recently a $20 million Series B capital raise in 2017. Evolve has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering, with a series of upcoming trials scheduled across both human and animal health applications. With a strong portfolio of intellectual property developed at UC Davis, a world-class management team plus blue-chip investors, and an unwavering dedication to allowing science to direct our product development, Evolve continues to expand it`s pipeline of next generation microbiome-based solutions to establish, restore, and maintain a healthy gut microbiome.